The H1 23/24 results were marginally behind the company-compiled consensus. The full-year sales guidance was nonetheless unchanged, suggesting better growth in the H2. The profitability guidance was moderated but was still better than the market had expected which, together with the H2 sales promise, perhaps triggered a strongly positive share price reaction earlier today. Furthermore, with the improving hearing aids market dynamics (also acknowledged by the peers), incremental growth – especia ....